Diabetes Care and Glycemic Control during the COVID-19 Pandemic in the United States

TY - JOUR

T1 - Diabetes Care and Glycemic Control during the COVID-19 Pandemic in the United States

AU - Patel, Sadiq Y.

AU - McCoy, Rozalina G.

AU - Barnett, Michael L.

AU - Shah, Nilay D.

AU - Mehrotra, Ateev

N1 - Funding Information: Conflict of Interest Disclosures: Mr Johnston reported receiving grants from the US Food and Drug Administration (FDA) through the Yale University–Mayo Clinic Center of Excellence in Regulatory Science and Innovation program. Dr Dhruva reported receiving research support from the National Heart, Lung, and Blood Institute of the National Institutes of Health (K12HL138046); the FDA; the Medical Device Innovation Consortium as part of National Evaluation System for Health Technology Coordinating Center; Arnold Ventures; and the Greenwall Foundation. Dr Ross reported receiving research support through Yale University from Johnson and Johnson to develop methods of clinical trial data sharing; the FDA to establish the Yale University–Mayo Clinic Center of Excellence in Regulatory Science and Innovation program (U01FD005938); the Medical Device Innovation Consortium as part of the National Evaluation System for Health Technology Coordinating Center; the Agency for Healthcare Research and Quality (R01HS022882); the National Heart, Lung, and Blood Institute of the National Institutes of Health (R01HS025164 and R01HL144644); and Arnold Ventures to establish the Good Pharma Scorecard at Bioethics International and the Collaboration for Research Integrity and Transparency at Yale. No other disclosures were reported. Funding Information: Administrative, technical, or material support: McCoy, Mehrotra. Supervision: Mehrotra. Conflict of Interest Disclosures: Dr McCoy reported grants from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) during the conduct of the study; grants from AARP and grants from NIDDK outside the submitted work. Dr Shah reported research support through Mayo Clinic from the US Food and Drug Administration to establish the Yale-Mayo Clinic Center for Excellence in Regulatory Science and Innovation (CERSI) program (U01FD005938); the Centers of Medicare and Medicaid Innovation under the Transforming Clinical Practice Initiative (TCPI); the Agency for Healthcare Research and Quality (R01HS025164; R01HS025402; R03HS025517; K12HS026379); the National Heart, Lung and Blood Institute of the National Institutes of Health (NIH) (R56HL130496; R01HL131535; R01HL151662); the National Science Foundation; from the Medical Device Innovation Consortium as part of the National Evaluation System for Health Technology (NEST) and the Patient Centered Outcomes Research Institute (PCORI) to develop a Clinical Data Research Network (LHSNet). Dr Mehrotra reported grants from Commonwealth Fund during the conduct of the study. No other disclosures were reported. Funding/Support: This project was supported by the Commonwealth Fund. There was also support from the National Institute of Diabetes and Digestive and Kidney Diseases (K23DK114497; RGM), National Institute on Aging of the National Institutes of Health (K23 AG058806-01; MLB), and National Institute of Mental Health (T32MH019733; SYP). Role of the Funder/Sponsor: The Commonwealth Fund and the National Institutes of Health had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

PY - 2021/10

Y1 - 2021/10

UR - http://www.scopus.com/inward/record.url?scp=85109573903&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85109573903&partnerID=8YFLogxK

U2 - 10.1001/jamainternmed.2021.3047

DO - 10.1001/jamainternmed.2021.3047

M3 - Letter

C2 - 34228043

AN - SCOPUS:85109573903

SN - 2168-6106

VL - 181

SP - 1412

EP - 1414

JO - JAMA internal medicine

JF - JAMA internal medicine

IS - 10

ER -